Skip to main content
Top
Published in: BMC Pregnancy and Childbirth 1/2018

Open Access 01-12-2018 | Research article

Screening of differentially expressed proteins from syncytiotrophoblast for severe early-onset preeclampsia in women with gestational diabetes mellitus using tandem mass tag quantitative proteomics

Authors: Xiaotong Sun, Tao Qu, Xiyan He, Xueping Yang, Nan Guo, Yan Mao, Xianghong Xu, Xiaodong Sun, Xuehong Zhang, Weihua Wang

Published in: BMC Pregnancy and Childbirth | Issue 1/2018

Login to get access

Abstract

Background

Previous studies have revealed that women with gestational diabetes mellitus (GDM) have an increased risk of developing preeclampsia (PE). The possible reason is the abnormal lipid metabolism caused by GDM that leads to dysfunction of vascular endothelial cells and atherosclerosis, resulting in the onset of PE. However, studies focusing on the pathogenesis of PE in syncytiotrophoblast of GDM patients are lacking. This study aimed to compare differentially expressed proteins from syncytiotrophoblast between women with GDM and women with GDM with subsequently developed PE.

Methods

Syncytiotrophoblast samples were obtained from pregnant women immediately after delivery. To explore the protein expression changes of syncytiotrophoblast that might explain the pathogenesis of PE in women with GDM, quantitative proteomics was performed using tandem mass tag (TMT) isobaric tags and liquid chromatography-tandem mass spectrometry. Bioinformatics analysis was performed to enrich the biological processes that these differentially expressed proteins were involved in.

Results

A total of 28,234 unique peptides and 4140 proteins were identified in all samples. Among them, 23 differentially expressed proteins were identified between patients with GDM and patients with GDM with subsequently developed PE. Therein, 11 proteins were upregulated and 12 proteins were downregulated. Two relative proteins (FLT1 and PABPC4) were independently verified using immunoblotting analysis. Bioinformatic results indicated that the onset of PE in patients with GDM is a multifactorial disorder, involving factors such as apoptosis, transcriptional misregulation, oxidative stress, lipid metabolism, cell infiltration and migration, and angiogenesis.

Conclusion

These results indicated that the inadequacy of endometrium infiltration, angiogenic disorder, and oxidative stress in syncytiotrophoblast are more likely to occur in patients with GDM and may be the potential mechanisms leading to such patients secondarily developing severe early-onset PE.
Literature
1.
go back to reference Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631–44.CrossRef Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631–44.CrossRef
2.
go back to reference Saleem S, McClure EM, Goudar SS, Patel A, Esamai F, Garces A, Chomba E, Althabe F, Moore J, Kodkany B, et al. A prospective study of maternal, fetal and neonatal deaths in low- and middle-income countries. Bull World Health Organ. 2014;92(8):605–12.CrossRef Saleem S, McClure EM, Goudar SS, Patel A, Esamai F, Garces A, Chomba E, Althabe F, Moore J, Kodkany B, et al. A prospective study of maternal, fetal and neonatal deaths in low- and middle-income countries. Bull World Health Organ. 2014;92(8):605–12.CrossRef
3.
go back to reference Auer J, Camoin L, Guillonneau F, Rigourd V, Chelbi ST, Leduc M, Laparre J, Mignot TM, Vaiman D. Serum profile in preeclampsia and intra-uterine growth restriction revealed by iTRAQ technology. J Proteome. 2010;73(5):1004–17.CrossRef Auer J, Camoin L, Guillonneau F, Rigourd V, Chelbi ST, Leduc M, Laparre J, Mignot TM, Vaiman D. Serum profile in preeclampsia and intra-uterine growth restriction revealed by iTRAQ technology. J Proteome. 2010;73(5):1004–17.CrossRef
4.
go back to reference Montoro MN, Kjos SL, Chandler M, Peters RK, Xiang AH, Buchanan TA. Insulin resistance and preeclampsia in gestational diabetes mellitus. Diabetes Care. 2005;28(8):1995–2000.CrossRef Montoro MN, Kjos SL, Chandler M, Peters RK, Xiang AH, Buchanan TA. Insulin resistance and preeclampsia in gestational diabetes mellitus. Diabetes Care. 2005;28(8):1995–2000.CrossRef
5.
go back to reference von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22(2):143–8.CrossRef von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22(2):143–8.CrossRef
6.
go back to reference Nadeau-Vallee M, Obari D, Palacios J, Brien ME, Duval C, Chemtob S, Girard S. Sterile inflammation and pregnancy complications: a review. Reproduction. 2016;152(6):R277–92.CrossRef Nadeau-Vallee M, Obari D, Palacios J, Brien ME, Duval C, Chemtob S, Girard S. Sterile inflammation and pregnancy complications: a review. Reproduction. 2016;152(6):R277–92.CrossRef
7.
go back to reference Nelson DB, Ziadie MS, McIntire DD, Rogers BB, Leveno KJ: Placental pathology suggesting that preeclampsia is more than one disease. Am J Obstet Gynecol 2014, 210(1):66 e61–67. Nelson DB, Ziadie MS, McIntire DD, Rogers BB, Leveno KJ: Placental pathology suggesting that preeclampsia is more than one disease. Am J Obstet Gynecol 2014, 210(1):66 e61–67.
8.
go back to reference Villa PM, Marttinen P, Gillberg J, Lokki AI, Majander K, Orden MR, Taipale P, Pesonen A, Raikkonen K, Hamalainen E, et al. Cluster analysis to estimate the risk of preeclampsia in the high-risk prediction and prevention of preeclampsia and intrauterine growth restriction (PREDO) study. PLoS One. 2017;12(3):e0174399.CrossRef Villa PM, Marttinen P, Gillberg J, Lokki AI, Majander K, Orden MR, Taipale P, Pesonen A, Raikkonen K, Hamalainen E, et al. Cluster analysis to estimate the risk of preeclampsia in the high-risk prediction and prevention of preeclampsia and intrauterine growth restriction (PREDO) study. PLoS One. 2017;12(3):e0174399.CrossRef
9.
go back to reference Singh A, Subramani E, Datta Ray C, Rapole S, Chaudhury K. Proteomic-driven biomarker discovery in gestational diabetes mellitus: a review. J Proteome. 2015;127(Pt A):44–9.CrossRef Singh A, Subramani E, Datta Ray C, Rapole S, Chaudhury K. Proteomic-driven biomarker discovery in gestational diabetes mellitus: a review. J Proteome. 2015;127(Pt A):44–9.CrossRef
10.
go back to reference Schneider S, Freerksen N, Rohrig S, Hoeft B, Maul H. Gestational diabetes and preeclampsia--similar risk factor profiles? Early Hum Dev. 2012;88(3):179–84.CrossRef Schneider S, Freerksen N, Rohrig S, Hoeft B, Maul H. Gestational diabetes and preeclampsia--similar risk factor profiles? Early Hum Dev. 2012;88(3):179–84.CrossRef
11.
go back to reference Mrema D, Lie RT, Ostbye T, Mahande MJ, Daltveit AK. The association between pre pregnancy body mass index and risk of preeclampsia: a registry based study from Tanzania. BMC Pregnancy Childbirth. 2018;18(1):56.CrossRef Mrema D, Lie RT, Ostbye T, Mahande MJ, Daltveit AK. The association between pre pregnancy body mass index and risk of preeclampsia: a registry based study from Tanzania. BMC Pregnancy Childbirth. 2018;18(1):56.CrossRef
12.
go back to reference Nerenberg KA, Johnson JA, Kaul P. Risk of preeclampsia in pregnant women with gestational diabetes in Alberta. Pregnancy Hypertens. 2012;2(3):323–4.CrossRef Nerenberg KA, Johnson JA, Kaul P. Risk of preeclampsia in pregnant women with gestational diabetes in Alberta. Pregnancy Hypertens. 2012;2(3):323–4.CrossRef
13.
go back to reference Ostlund I, Haglund B, Hanson U. Gestational diabetes and preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2004;113(1):12–6.CrossRef Ostlund I, Haglund B, Hanson U. Gestational diabetes and preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2004;113(1):12–6.CrossRef
14.
go back to reference Phaloprakarn C, Tangjitgamol S. Risk assessment for preeclampsia in women with gestational diabetes mellitus. J Perinat Med. 2009;37(6):617–21.CrossRef Phaloprakarn C, Tangjitgamol S. Risk assessment for preeclampsia in women with gestational diabetes mellitus. J Perinat Med. 2009;37(6):617–21.CrossRef
15.
go back to reference Llurba E, Casals E, Dominguez C, Delgado J, Mercade I, Crispi F, Martin-Gallan P, Cabero L, Gratacos E. Atherogenic lipoprotein subfraction profile in preeclamptic women with and without high triglycerides: different pathophysiologic subsets in preeclampsia. Metabolism. 2005;54(11):1504–9.CrossRef Llurba E, Casals E, Dominguez C, Delgado J, Mercade I, Crispi F, Martin-Gallan P, Cabero L, Gratacos E. Atherogenic lipoprotein subfraction profile in preeclamptic women with and without high triglycerides: different pathophysiologic subsets in preeclampsia. Metabolism. 2005;54(11):1504–9.CrossRef
16.
go back to reference Qi WH, Zheng MY, Li C, Xu L, Xu JE. Screening of differential proteins of placenta tissues in patients with pre-eclampsia by iTRAQ proteomics techniques. Minerva Med. 2017;108(5):389–95.PubMed Qi WH, Zheng MY, Li C, Xu L, Xu JE. Screening of differential proteins of placenta tissues in patients with pre-eclampsia by iTRAQ proteomics techniques. Minerva Med. 2017;108(5):389–95.PubMed
17.
go back to reference Kolla V, Jeno P, Moes S, Lapaire O, Hoesli I, Hahn S. Quantitative proteomic (iTRAQ) analysis of 1st trimester maternal plasma samples in pregnancies at risk for preeclampsia. J Biomed Biotechnol. 2012;2012:305964.CrossRef Kolla V, Jeno P, Moes S, Lapaire O, Hoesli I, Hahn S. Quantitative proteomic (iTRAQ) analysis of 1st trimester maternal plasma samples in pregnancies at risk for preeclampsia. J Biomed Biotechnol. 2012;2012:305964.CrossRef
18.
go back to reference Li H, Han L, Yang Z, Huang W, Zhang X, Gu Y, Li Y, Liu X, Zhou L, Hu J, et al. Differential proteomic analysis of Syncytiotrophoblast extracellular vesicles from early-onset severe preeclampsia, using 8-Plex iTRAQ labeling coupled with 2D Nano LC-MS/MS. Cell Physiol Biochem. 2015;36(3):1116–30.CrossRef Li H, Han L, Yang Z, Huang W, Zhang X, Gu Y, Li Y, Liu X, Zhou L, Hu J, et al. Differential proteomic analysis of Syncytiotrophoblast extracellular vesicles from early-onset severe preeclampsia, using 8-Plex iTRAQ labeling coupled with 2D Nano LC-MS/MS. Cell Physiol Biochem. 2015;36(3):1116–30.CrossRef
19.
go back to reference Pan HT, Guo MX, Xiong YM, Ren J, Zhang JY, Gao Q, Ke ZH, Xu GF, Tan YJ, Sheng JZ, et al. Differential proteomic analysis of umbilical artery tissue from preeclampsia patients, using iTRAQ isobaric tags and 2D nano LC-MS/MS. J Proteome. 2015;112:262–73.CrossRef Pan HT, Guo MX, Xiong YM, Ren J, Zhang JY, Gao Q, Ke ZH, Xu GF, Tan YJ, Sheng JZ, et al. Differential proteomic analysis of umbilical artery tissue from preeclampsia patients, using iTRAQ isobaric tags and 2D nano LC-MS/MS. J Proteome. 2015;112:262–73.CrossRef
20.
go back to reference Li B, Yang H, Zhang W, Shi Y, Qin S, Wei Y, He Y, Yang W, Jiang S, Jin H. Fatty acid-binding protein 4 predicts gestational hypertension and preeclampsia in women with gestational diabetes mellitus. PLoS One. 2018;13(2):e0192347.CrossRef Li B, Yang H, Zhang W, Shi Y, Qin S, Wei Y, He Y, Yang W, Jiang S, Jin H. Fatty acid-binding protein 4 predicts gestational hypertension and preeclampsia in women with gestational diabetes mellitus. PLoS One. 2018;13(2):e0192347.CrossRef
21.
go back to reference Kawauchi J, Zhang C, Nobori K, Hashimoto Y, Adachi MT, Noda A, Sunamori M, Kitajima S. Transcriptional repressor activating transcription factor 3 protects human umbilical vein endothelial cells from tumor necrosis factor-alpha-induced apoptosis through down-regulation of p53 transcription. J Biol Chem. 2002;277(41):39025–34.CrossRef Kawauchi J, Zhang C, Nobori K, Hashimoto Y, Adachi MT, Noda A, Sunamori M, Kitajima S. Transcriptional repressor activating transcription factor 3 protects human umbilical vein endothelial cells from tumor necrosis factor-alpha-induced apoptosis through down-regulation of p53 transcription. J Biol Chem. 2002;277(41):39025–34.CrossRef
22.
go back to reference Kaitu'u-Lino TJ, Brownfoot FC, Hastie R, Chand A, Cannon P, Deo M, Tuohey L, Whitehead C, Hannan NJ, Tong S. Activating transcription factor 3 is reduced in Preeclamptic placentas and negatively regulates sFlt-1 (soluble fms-like tyrosine kinase 1), soluble Endoglin, and Proinflammatory cytokines in placenta. Hypertension. 2017;70(5):1014–24.CrossRef Kaitu'u-Lino TJ, Brownfoot FC, Hastie R, Chand A, Cannon P, Deo M, Tuohey L, Whitehead C, Hannan NJ, Tong S. Activating transcription factor 3 is reduced in Preeclamptic placentas and negatively regulates sFlt-1 (soluble fms-like tyrosine kinase 1), soluble Endoglin, and Proinflammatory cytokines in placenta. Hypertension. 2017;70(5):1014–24.CrossRef
23.
go back to reference He B, Yang X, Li Y, Huang D, Xu X, Yang W, Dai Y, Zhang H, Chen Z, Cheng W. TLR9 (toll-like receptor 9) agonist suppresses angiogenesis by differentially regulating VEGFA (vascular endothelial growth factor a) and sFLT1 (soluble vascular endothelial growth factor receptor 1) in preeclampsia. Hypertension. 2018;71(4):671–80.CrossRef He B, Yang X, Li Y, Huang D, Xu X, Yang W, Dai Y, Zhang H, Chen Z, Cheng W. TLR9 (toll-like receptor 9) agonist suppresses angiogenesis by differentially regulating VEGFA (vascular endothelial growth factor a) and sFLT1 (soluble vascular endothelial growth factor receptor 1) in preeclampsia. Hypertension. 2018;71(4):671–80.CrossRef
24.
go back to reference Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab. 2003;88(5):2348–51.CrossRef Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab. 2003;88(5):2348–51.CrossRef
25.
go back to reference Vuorela P, Helske S, Hornig C, Alitalo K, Weich H, Halmesmaki E. Amniotic fluid--soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol. 2000;95(3):353–7.PubMed Vuorela P, Helske S, Hornig C, Alitalo K, Weich H, Halmesmaki E. Amniotic fluid--soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol. 2000;95(3):353–7.PubMed
26.
go back to reference Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004;95(9):884–91.CrossRef Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004;95(9):884–91.CrossRef
27.
go back to reference Levine RJQC, Maynard SE, Yu KF, Epstein FH, Karumanchi SA. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol. 2006;194:1034–41.CrossRef Levine RJQC, Maynard SE, Yu KF, Epstein FH, Karumanchi SA. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol. 2006;194:1034–41.CrossRef
28.
go back to reference Palmer KRK-LT, Hastie R, Hannan NJ, Ye L, Binder N, Cannon P, Tuohey L, Johns TG, Shub A, et al. Placental-specific sFLT-1 e15a protein is increased in preeclampsia, antagonizes vascular endothelial growth factor signaling, and has antiangiogenic activity. Hypertension. 2015;66:1251–9.CrossRef Palmer KRK-LT, Hastie R, Hannan NJ, Ye L, Binder N, Cannon P, Tuohey L, Johns TG, Shub A, et al. Placental-specific sFLT-1 e15a protein is increased in preeclampsia, antagonizes vascular endothelial growth factor signaling, and has antiangiogenic activity. Hypertension. 2015;66:1251–9.CrossRef
29.
go back to reference Levine RJMS, Qian C, Lim K-H, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, et al. Circulating Angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.CrossRef Levine RJMS, Qian C, Lim K-H, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, et al. Circulating Angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.CrossRef
30.
go back to reference Shibata ERA, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. Endocrinol Metab J Clin. 2005;90:4895–903.CrossRef Shibata ERA, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. Endocrinol Metab J Clin. 2005;90:4895–903.CrossRef
31.
go back to reference Souders CAMS, Yan J, Wang Y, Boatright NK, Sedan J, Balyozian D, Cheslock PS, Molrine DC, Simas TA. Circulating levels of sFlt1 splice variants as predictive markers for the development of preeclampsia. Int J Mol Sci. 2015;16:12436–53.CrossRef Souders CAMS, Yan J, Wang Y, Boatright NK, Sedan J, Balyozian D, Cheslock PS, Molrine DC, Simas TA. Circulating levels of sFlt1 splice variants as predictive markers for the development of preeclampsia. Int J Mol Sci. 2015;16:12436–53.CrossRef
32.
go back to reference McKeeman GCAJ, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol. 2004;191:1240–6.CrossRef McKeeman GCAJ, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol. 2004;191:1240–6.CrossRef
33.
go back to reference Chaiworapongsa TRR, Espinoza J, Bujold E, Mee Kim Y, Goncalves LF, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004;190:1541–7.CrossRef Chaiworapongsa TRR, Espinoza J, Bujold E, Mee Kim Y, Goncalves LF, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004;190:1541–7.CrossRef
34.
go back to reference Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol. 1995;129(1):255–65.CrossRef Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol. 1995;129(1):255–65.CrossRef
35.
go back to reference Shyu MK, Chen CW, Lin NY, Liao WC, Chen CH, Lin CJ, Huang HC, Lee JJ, Huang MJ, Tseng GF, et al. MUC1 expression is elevated in severe preeclamptic placentas and suppresses trophoblast cell invasion via beta1-integrin signaling. J Clin Endocrinol Metab. 2011;96(12):3759–67.CrossRef Shyu MK, Chen CW, Lin NY, Liao WC, Chen CH, Lin CJ, Huang HC, Lee JJ, Huang MJ, Tseng GF, et al. MUC1 expression is elevated in severe preeclamptic placentas and suppresses trophoblast cell invasion via beta1-integrin signaling. J Clin Endocrinol Metab. 2011;96(12):3759–67.CrossRef
36.
go back to reference Masuda J, Takayama E, Satoh A, Ida M, Shinohara T, Kojima-Aikawa K, Ohsuzu F, Nakanishi K, Kuroda K, Murakami M, et al. Levels of annexin IV and V in the plasma of pregnant and postpartum women. Thromb Haemost. 2004;91(6):1129–36.CrossRef Masuda J, Takayama E, Satoh A, Ida M, Shinohara T, Kojima-Aikawa K, Ohsuzu F, Nakanishi K, Kuroda K, Murakami M, et al. Levels of annexin IV and V in the plasma of pregnant and postpartum women. Thromb Haemost. 2004;91(6):1129–36.CrossRef
37.
go back to reference Yao HS, Sun C, Li XX, Wang Y, Jin KZ, Zhang XP, Hu ZQ. Annexin A4-nuclear factor-kappaB feedback circuit regulates cell malignant behavior and tumor growth in gallbladder cancer. Sci Rep. 2016;6:31056.CrossRef Yao HS, Sun C, Li XX, Wang Y, Jin KZ, Zhang XP, Hu ZQ. Annexin A4-nuclear factor-kappaB feedback circuit regulates cell malignant behavior and tumor growth in gallbladder cancer. Sci Rep. 2016;6:31056.CrossRef
38.
go back to reference Yang JI, Kong TW, Kim HS, Kim HY. The proteomic analysis of human placenta with pre-eclampsia and Normal pregnancy. J Korean Med Sci. 2015;30(6):770–8.CrossRef Yang JI, Kong TW, Kim HS, Kim HY. The proteomic analysis of human placenta with pre-eclampsia and Normal pregnancy. J Korean Med Sci. 2015;30(6):770–8.CrossRef
39.
go back to reference Gratton RJ, Asano H, Han VK. The regional expression of insulin-like growth factor II (IGF-II) and insulin-like growth factor binding protein-1 (IGFBP-1) in the placentae of women with pre-eclampsia. Placenta. 2002;23(4):303–10.CrossRef Gratton RJ, Asano H, Han VK. The regional expression of insulin-like growth factor II (IGF-II) and insulin-like growth factor binding protein-1 (IGFBP-1) in the placentae of women with pre-eclampsia. Placenta. 2002;23(4):303–10.CrossRef
40.
go back to reference Overgaard MT, Boldt HB, Laursen LS, Sottrup-Jensen L, Conover CA, Oxvig C. Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J Biol Chem. 2001;276(24):21849–53.CrossRef Overgaard MT, Boldt HB, Laursen LS, Sottrup-Jensen L, Conover CA, Oxvig C. Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J Biol Chem. 2001;276(24):21849–53.CrossRef
41.
go back to reference Macintire K, Tuohey L, Ye L, Palmer K, Gantier M, Tong S, Kaitu'u-Lino TJ. PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia. Reprod Fertil Dev. 2014;26(2):351–7.CrossRef Macintire K, Tuohey L, Ye L, Palmer K, Gantier M, Tong S, Kaitu'u-Lino TJ. PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia. Reprod Fertil Dev. 2014;26(2):351–7.CrossRef
42.
go back to reference Wagner PK, Otomo A, Christians JK. Regulation of pregnancy-associated plasma protein A2 (PAPPA2) in a human placental trophoblast cell line (BeWo). Reprod Biol Endocrinol. 2011;9:48.CrossRef Wagner PK, Otomo A, Christians JK. Regulation of pregnancy-associated plasma protein A2 (PAPPA2) in a human placental trophoblast cell line (BeWo). Reprod Biol Endocrinol. 2011;9:48.CrossRef
43.
go back to reference Kloverpris S, Gaidamauskas E, Rasmussen LC, Overgaard MT, Kronborg C, Knudsen UB, Christiansen M, Kumar A, Oxvig C. A robust immunoassay for pregnancy-associated plasma protein-A2 based on analysis of circulating antigen: establishment of normal ranges in pregnancy. Mol Hum Reprod. 2013;19(11):756–63.CrossRef Kloverpris S, Gaidamauskas E, Rasmussen LC, Overgaard MT, Kronborg C, Knudsen UB, Christiansen M, Kumar A, Oxvig C. A robust immunoassay for pregnancy-associated plasma protein-A2 based on analysis of circulating antigen: establishment of normal ranges in pregnancy. Mol Hum Reprod. 2013;19(11):756–63.CrossRef
44.
go back to reference Ejima K, Nanri H, Toki N, Kashimura M, Ikeda M. Localization of thioredoxin reductase and thioredoxin in normal human placenta and their protective effect against oxidative stress. Placenta. 1999;20(1):95–101.CrossRef Ejima K, Nanri H, Toki N, Kashimura M, Ikeda M. Localization of thioredoxin reductase and thioredoxin in normal human placenta and their protective effect against oxidative stress. Placenta. 1999;20(1):95–101.CrossRef
45.
go back to reference Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Katkuri S, DuBois RN. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005;280(5):3217–23.CrossRef Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Katkuri S, DuBois RN. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005;280(5):3217–23.CrossRef
46.
go back to reference Schoof E, Girstl M, Frobenius W, Kirschbaum M, Dorr HG, Rascher W, Dotsch J. Decreased gene expression of 11beta-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia. J Clin Endocrinol Metab. 2001;86(3):1313–7.PubMed Schoof E, Girstl M, Frobenius W, Kirschbaum M, Dorr HG, Rascher W, Dotsch J. Decreased gene expression of 11beta-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia. J Clin Endocrinol Metab. 2001;86(3):1313–7.PubMed
47.
go back to reference May D, Itin A, Gal O, Kalinski H, Feinstein E, Keshet E. Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer. Oncogene. 2005;24(6):1011–20.CrossRef May D, Itin A, Gal O, Kalinski H, Feinstein E, Keshet E. Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer. Oncogene. 2005;24(6):1011–20.CrossRef
Metadata
Title
Screening of differentially expressed proteins from syncytiotrophoblast for severe early-onset preeclampsia in women with gestational diabetes mellitus using tandem mass tag quantitative proteomics
Authors
Xiaotong Sun
Tao Qu
Xiyan He
Xueping Yang
Nan Guo
Yan Mao
Xianghong Xu
Xiaodong Sun
Xuehong Zhang
Weihua Wang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Pregnancy and Childbirth / Issue 1/2018
Electronic ISSN: 1471-2393
DOI
https://doi.org/10.1186/s12884-018-2066-9

Other articles of this Issue 1/2018

BMC Pregnancy and Childbirth 1/2018 Go to the issue